CLINICAL RESEARCH ON ANTIANGIOGENIC THERAPY
A promising novel target for anti-cancer therapy is the tumour vasculature. Both primary tumour growth and the formation of metastasis depend on the establishment of new blood vessels from preexisting ones, a process called angiogenesis. Inhibition of angiogenesis and targeting of the tumour vascula...
Gespeichert in:
| Veröffentlicht in: | Pharmacological research 1998-01, Vol.37 (1), p.1-16 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 16 |
|---|---|
| container_issue | 1 |
| container_start_page | 1 |
| container_title | Pharmacological research |
| container_volume | 37 |
| creator | KUIPER, R.A.J. SCHELLENS, J.H.M. BLIJHAM, G.H. BEIJNEN, J.H. VOEST, E.E. |
| description | A promising novel target for anti-cancer therapy is the tumour vasculature. Both primary tumour growth and the formation of metastasis depend on the establishment of new blood vessels from preexisting ones, a process called angiogenesis. Inhibition of angiogenesis and targeting of the tumour vasculature are highly effective in controlling tumour growth. Several natural and synthetic compounds have been developed and are currently tested in pre-clinical and clinical studies. This review intends to provide an overview of agents with antiangiogenic activity and the early clinical experience with these drugs. |
| doi_str_mv | 10.1006/phrs.1997.0268 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79729486</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1043661897902681</els_id><sourcerecordid>79729486</sourcerecordid><originalsourceid>FETCH-LOGICAL-c339t-f76d6d3575373471b26ae0a63bd9da1bbd6b838f6a882a38d0eb27c6c29ba7153</originalsourceid><addsrcrecordid>eNp1kM9LwzAYhoMoU6dXb0JPXqQ1adovybGMuhVGJ3MePIX8Kla2dSab4H9vy4Y3T1_gffN8fA9CdwQnBGN42n34kBAhWIJT4GfoimABMSEczod3RmMAwi_RdQifGGORETxCI5FjmrHsCj1O5lVdTYp5tCxfy2I5mUWLOirqVVXU02oxLfswWs3KZfHyfoMuGrUO7vY0x-jtuVxNZvF8MR0QsaFU7OOGgQVLc5ZT1i8hOgXlsAKqrbCKaG1Bc8obUJyninKLnU6ZAZMKrRjJ6Rg9HLk7330dXNjLTRuMW6_V1nWHIJlgqcg49MXkWDS-C8G7Ru58u1H-RxIsBztysCMHO3Kw03-4P5EPeuPsX_2ko8_5MXf9ed-t8zKY1m2Ns613Zi9t1_6H_gU-_26L</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79729486</pqid></control><display><type>article</type><title>CLINICAL RESEARCH ON ANTIANGIOGENIC THERAPY</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>KUIPER, R.A.J. ; SCHELLENS, J.H.M. ; BLIJHAM, G.H. ; BEIJNEN, J.H. ; VOEST, E.E.</creator><creatorcontrib>KUIPER, R.A.J. ; SCHELLENS, J.H.M. ; BLIJHAM, G.H. ; BEIJNEN, J.H. ; VOEST, E.E.</creatorcontrib><description>A promising novel target for anti-cancer therapy is the tumour vasculature. Both primary tumour growth and the formation of metastasis depend on the establishment of new blood vessels from preexisting ones, a process called angiogenesis. Inhibition of angiogenesis and targeting of the tumour vasculature are highly effective in controlling tumour growth. Several natural and synthetic compounds have been developed and are currently tested in pre-clinical and clinical studies. This review intends to provide an overview of agents with antiangiogenic activity and the early clinical experience with these drugs.</description><identifier>ISSN: 1043-6618</identifier><identifier>EISSN: 1096-1186</identifier><identifier>DOI: 10.1006/phrs.1997.0268</identifier><identifier>PMID: 9503474</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>angiogenesis, cancer, pharmacology, clinical trials, design ; Antibodies - therapeutic use ; Antineoplastic Agents - therapeutic use ; Basement Membrane - drug effects ; Clinical Trials as Topic ; Endothelium, Vascular - drug effects ; Humans ; Neoplasms - secretion ; Neoplasms - therapy ; Neovascularization, Pathologic - therapy</subject><ispartof>Pharmacological research, 1998-01, Vol.37 (1), p.1-16</ispartof><rights>1998 The Italian Pharmacological Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c339t-f76d6d3575373471b26ae0a63bd9da1bbd6b838f6a882a38d0eb27c6c29ba7153</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1043661897902681$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9503474$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KUIPER, R.A.J.</creatorcontrib><creatorcontrib>SCHELLENS, J.H.M.</creatorcontrib><creatorcontrib>BLIJHAM, G.H.</creatorcontrib><creatorcontrib>BEIJNEN, J.H.</creatorcontrib><creatorcontrib>VOEST, E.E.</creatorcontrib><title>CLINICAL RESEARCH ON ANTIANGIOGENIC THERAPY</title><title>Pharmacological research</title><addtitle>Pharmacol Res</addtitle><description>A promising novel target for anti-cancer therapy is the tumour vasculature. Both primary tumour growth and the formation of metastasis depend on the establishment of new blood vessels from preexisting ones, a process called angiogenesis. Inhibition of angiogenesis and targeting of the tumour vasculature are highly effective in controlling tumour growth. Several natural and synthetic compounds have been developed and are currently tested in pre-clinical and clinical studies. This review intends to provide an overview of agents with antiangiogenic activity and the early clinical experience with these drugs.</description><subject>angiogenesis, cancer, pharmacology, clinical trials, design</subject><subject>Antibodies - therapeutic use</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Basement Membrane - drug effects</subject><subject>Clinical Trials as Topic</subject><subject>Endothelium, Vascular - drug effects</subject><subject>Humans</subject><subject>Neoplasms - secretion</subject><subject>Neoplasms - therapy</subject><subject>Neovascularization, Pathologic - therapy</subject><issn>1043-6618</issn><issn>1096-1186</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM9LwzAYhoMoU6dXb0JPXqQ1adovybGMuhVGJ3MePIX8Kla2dSab4H9vy4Y3T1_gffN8fA9CdwQnBGN42n34kBAhWIJT4GfoimABMSEczod3RmMAwi_RdQifGGORETxCI5FjmrHsCj1O5lVdTYp5tCxfy2I5mUWLOirqVVXU02oxLfswWs3KZfHyfoMuGrUO7vY0x-jtuVxNZvF8MR0QsaFU7OOGgQVLc5ZT1i8hOgXlsAKqrbCKaG1Bc8obUJyninKLnU6ZAZMKrRjJ6Rg9HLk7330dXNjLTRuMW6_V1nWHIJlgqcg49MXkWDS-C8G7Ru58u1H-RxIsBztysCMHO3Kw03-4P5EPeuPsX_2ko8_5MXf9ed-t8zKY1m2Ns613Zi9t1_6H_gU-_26L</recordid><startdate>199801</startdate><enddate>199801</enddate><creator>KUIPER, R.A.J.</creator><creator>SCHELLENS, J.H.M.</creator><creator>BLIJHAM, G.H.</creator><creator>BEIJNEN, J.H.</creator><creator>VOEST, E.E.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199801</creationdate><title>CLINICAL RESEARCH ON ANTIANGIOGENIC THERAPY</title><author>KUIPER, R.A.J. ; SCHELLENS, J.H.M. ; BLIJHAM, G.H. ; BEIJNEN, J.H. ; VOEST, E.E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c339t-f76d6d3575373471b26ae0a63bd9da1bbd6b838f6a882a38d0eb27c6c29ba7153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>angiogenesis, cancer, pharmacology, clinical trials, design</topic><topic>Antibodies - therapeutic use</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Basement Membrane - drug effects</topic><topic>Clinical Trials as Topic</topic><topic>Endothelium, Vascular - drug effects</topic><topic>Humans</topic><topic>Neoplasms - secretion</topic><topic>Neoplasms - therapy</topic><topic>Neovascularization, Pathologic - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KUIPER, R.A.J.</creatorcontrib><creatorcontrib>SCHELLENS, J.H.M.</creatorcontrib><creatorcontrib>BLIJHAM, G.H.</creatorcontrib><creatorcontrib>BEIJNEN, J.H.</creatorcontrib><creatorcontrib>VOEST, E.E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmacological research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KUIPER, R.A.J.</au><au>SCHELLENS, J.H.M.</au><au>BLIJHAM, G.H.</au><au>BEIJNEN, J.H.</au><au>VOEST, E.E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CLINICAL RESEARCH ON ANTIANGIOGENIC THERAPY</atitle><jtitle>Pharmacological research</jtitle><addtitle>Pharmacol Res</addtitle><date>1998-01</date><risdate>1998</risdate><volume>37</volume><issue>1</issue><spage>1</spage><epage>16</epage><pages>1-16</pages><issn>1043-6618</issn><eissn>1096-1186</eissn><abstract>A promising novel target for anti-cancer therapy is the tumour vasculature. Both primary tumour growth and the formation of metastasis depend on the establishment of new blood vessels from preexisting ones, a process called angiogenesis. Inhibition of angiogenesis and targeting of the tumour vasculature are highly effective in controlling tumour growth. Several natural and synthetic compounds have been developed and are currently tested in pre-clinical and clinical studies. This review intends to provide an overview of agents with antiangiogenic activity and the early clinical experience with these drugs.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>9503474</pmid><doi>10.1006/phrs.1997.0268</doi><tpages>16</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1043-6618 |
| ispartof | Pharmacological research, 1998-01, Vol.37 (1), p.1-16 |
| issn | 1043-6618 1096-1186 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79729486 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | angiogenesis, cancer, pharmacology, clinical trials, design Antibodies - therapeutic use Antineoplastic Agents - therapeutic use Basement Membrane - drug effects Clinical Trials as Topic Endothelium, Vascular - drug effects Humans Neoplasms - secretion Neoplasms - therapy Neovascularization, Pathologic - therapy |
| title | CLINICAL RESEARCH ON ANTIANGIOGENIC THERAPY |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T11%3A17%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CLINICAL%20RESEARCH%20ON%20ANTIANGIOGENIC%20THERAPY&rft.jtitle=Pharmacological%20research&rft.au=KUIPER,%20R.A.J.&rft.date=1998-01&rft.volume=37&rft.issue=1&rft.spage=1&rft.epage=16&rft.pages=1-16&rft.issn=1043-6618&rft.eissn=1096-1186&rft_id=info:doi/10.1006/phrs.1997.0268&rft_dat=%3Cproquest_cross%3E79729486%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79729486&rft_id=info:pmid/9503474&rft_els_id=S1043661897902681&rfr_iscdi=true |